Charcot-Marie-Tooth disease: Emerging mechanisms and therapies

被引:28
|
作者
d'Ydewalle, Constantin [1 ,2 ,3 ]
Benoy, Veronick [1 ,2 ,3 ]
Van den Bosch, Ludo [1 ,2 ,3 ]
机构
[1] Univ Louvain, Neurobiol Lab, B-3000 Louvain, Belgium
[2] VIB, Vesalius Res Ctr, Louvain, Belgium
[3] Univ Louvain, Leuven Res Inst Neurodegenerat Dis LIND, B-3000 Louvain, Belgium
关键词
Charcot-Marie-Tooth disease (CMT); Axonal transport; Histone deacetylase 6 (HDAC6); HEREDITARY MOTOR NEUROPATHY; TRANSFER-RNA SYNTHETASE; MOUSE MODEL; INHERITED NEUROPATHIES; AXONAL NEUROPATHIES; SCHWANN-CELLS; MUTANT; MUTATIONS; TRANSPORT; PROTEIN;
D O I
10.1016/j.biocel.2012.04.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Charcot-Marie-Tooth disease is the most common inherited disorder of the peripheral nervous system. The disease is characterized by a progressive muscle weakness and atrophy, sensory loss, foot (and hand) deformities and steppage gait. While many of the genes associated with axonal CMT have been identified, to date it is unknown which mechanism(s) causes the disease. However, genetic findings indicate that the underlying mechanisms mainly converge to the axonal cytoskeleton. In this review, we will summarize the evidence for this pathogenic convergence. Furthermore, recent work with new transgenic mouse models has led to the identification of histone deacetylase 6 as a potential therapeutic target for inherited peripheral neuropathies. This enzyme deacetylates microtubules and plays a crucial role in the regulation of axonal transport. These findings offer new perspectives for a potential therapy to treat axonal Charcot-Marie-Tooth disease and other neurodegenerative disorders characterized by axonal transport defects. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1299 / 1304
页数:6
相关论文
共 50 条
  • [21] Charcot-Marie-Tooth disease and intracellular traffic
    Bucci, Cecilia
    Bakke, Oddmund
    Progida, Cinzia
    PROGRESS IN NEUROBIOLOGY, 2012, 99 (03) : 191 - 225
  • [22] Genetic epidemiology of Charcot-Marie-Tooth disease
    Braathen, G. J.
    ACTA NEUROLOGICA SCANDINAVICA, 2012, 126 : iv - 22
  • [23] Dynamin 2 in Charcot-Marie-Tooth Disease
    Tanabe, Kenji
    Takei, Kohji
    ACTA MEDICA OKAYAMA, 2012, 66 (03) : 183 - 190
  • [24] Molecular diagnosis of axonal forms of Charcot-Marie-Tooth disease
    Latour, P.
    Vial, C.
    REVUE NEUROLOGIQUE, 2009, 165 (12) : 1122 - 1126
  • [25] Clinical implications of genetic advances in Charcot-Marie-Tooth disease
    Rossor, Alexander M.
    Polke, James M.
    Houlden, Henry
    Reilly, Mary M.
    NATURE REVIEWS NEUROLOGY, 2013, 9 (10) : 562 - 571
  • [26] Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies
    Pisciotta, Chiara
    Saveri, Paola
    Pareyson, Davide
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2021, 21 (06) : 701 - 713
  • [27] Guidelines for molecular diagnosis of Charcot-Marie-Tooth disease
    Berciano, J.
    Sevilla, T.
    Casasnovas, C.
    Sivera, R.
    Vilchez, J. J.
    Infante, J.
    Ramon, C.
    Pelayo-Negro, A. L.
    Illa, I.
    NEUROLOGIA, 2012, 27 (03): : 169 - 178
  • [28] Neurofilament light, biomarkers, and Charcot-Marie-Tooth disease
    Pareyson, Davide
    Shy, Michael E.
    NEUROLOGY, 2018, 90 (06) : 257 - 259
  • [29] Schwann Cell and the Pathogenesis of Charcot-Marie-Tooth Disease
    Murakami, Tatsufumi
    Sunada, Yoshihide
    MYELIN: BASIC AND CLINICAL ADVANCES, 2019, 1190 : 301 - 321
  • [30] The Current State of Charcot-Marie-Tooth Disease Treatment
    Okamoto, Yuji
    Takashima, Hiroshi
    GENES, 2023, 14 (07)